课题基金 / 基金详情

EFFICACY AND SAFETY OF ORAL RIDOGREL AS MAINTENANCE FOR ULCERATIVE COLITIS

EFFICACY AND SAFETY OF ORAL RIDOGREL AS MAINTENANCE FOR ULCERATIVE COLITIS
口服利多格雷维持治疗溃疡性结肠炎的功效和安全性
批准号：
6121131
负责人：
ALAN L. BUCHMAN
金额：
$1.51万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/6121131
关键词：
clinical research drug screening /evaluation endoscopy enzyme inhibitors gastrointestinal agents gastrointestinal disorder chemotherapy histology human subject human therapy evaluation oral administration remission /regression ulcerative colitis

项目摘要

项目成果

ALAN L. BUCHMAN的其他基金

相关文献

中文摘要
翻译
本研究将确定低剂量利多格雷治疗 维持溃疡性结肠炎（UC）的缓解。 例患者 一项多中心试验将使他们的UC缓解， 先前在活动性UC中进行的利多格雷研究，或将处于缓解期 最多6个月的另一种药物。 他们将被随机分组 口服利多格雷0.5、2.5或5.0 mg/d，持续1年。 将通过主观症状评估和内镜检查对患者进行评估。 和组织学参数。
英文摘要
This study will determine the efficacy and safety of low dose ridogrel for the maintenance of remission of ulcerative colitis (UC). Patients in this multicenter trial will have achieved remission of their UC while in a previous study of ridogrel in active UC, or will have been in remission for a maximum of 6 months on another medication. They will be randomized to receive oral ridogrel at 0.5, 2.5, or 5.0 mg daily for one year. Patients will be evaluated by subjective symptom evaluation and endoscopic and histologic parameters.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TREATMENT OF HEPATIC STEATOSIS ASSOCIATED WITH TOTAL PARENTAL NUTRITION
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY
SAFETY AND EFFICACY OF ISIS 2302 IN STEROID DEPENDENT CROHN'S DISEASE